Should I buy or sell Athira Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHA shares. View ATHA analyst ratings or view top-rated stocks .

What is Athira Pharma's stock price target for 2024?

1 Wall Street analysts have issued twelve-month price objectives for Athira Pharma's stock. Their ATHA share price targets range from $5.00 to $19.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 482.5% from the stock's current price. View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts .

How have ATHA shares performed in 2024?

Athira Pharma's stock was trading at $2.43 on January 1st, 2024. Since then, ATHA shares have decreased by 15.2% and is now trading at $2.06. View the best growth stocks for 2024 here .

When is Athira Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATHA earnings forecast .

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, February, 22nd. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.25.

What ETF holds Athira Pharma's stock?

Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 3.87% of its portfolio.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH) , Intel (INTC) , Lumentum (LITE) , NIO (NIO) , NVIDIA (NVDA) , Boeing (BA) , Alibaba Group (BABA) , Beyond Meat (BYND) , Delta Air Lines (DAL) and Extreme Networks (EXTR) .

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirador Capital Partners LP (0.05%). Insiders that own company stock include Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington. View institutional ownership trends .

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ATHA Stock Alerts

$2.06

-0.05 (-2.37%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.02
▼
$2.20
50-Day Range: $2.06
▼
$4.15
52-Week Range: $1.33
▼
$4.30

Volume: 197,947 shs
Average Volume: 401,369 shs
Market Capitalization: $78.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get Athira Pharma alerts:

Athira Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 482.5% Upside
$12.00 Price Target
Short Interest: Healthy
2.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.86) to ($3.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

555th out of 919 stocks

Biological Products, Except Diagnostic Industry

88th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Athira Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Athira Pharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.86% of the float of Athira Pharma has been sold short.
Short Interest Ratio / Days to Cover
Athira Pharma has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Athira Pharma has recently increased by 3.13%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Athira Pharma does not currently pay a dividend.
Dividend Growth
Athira Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATHA.

1.8

News and Social Media Coverage

News Sentiment
Athira Pharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Athira Pharma this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Athira Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.90% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Athira Pharma are expected to decrease in the coming year, from ($2.86) to ($3.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Athira Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Athira Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Athira Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Athira Pharma Stock (NASDAQ:ATHA)

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATHA Stock News Headlines

April 17, 2024 | msn.com

Athira Pharma (ATHA) Price Target Increased by 7.49% to 7.57

April 15, 2024 | finanznachrichten.de

Athira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | markets.businessinsider.com

Athira Pharma Appoints Javier San Martin As New Chief Medical Officer

April 15, 2024 | globenewswire.com

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

April 11, 2024 | finanznachrichten.de

Athira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

April 11, 2024 | finance.yahoo.com

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

April 11, 2024 | globenewswire.com

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | globenewswire.com

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

March 20, 2024 | finance.yahoo.com

Athira Pharma, Inc. (ATHA)

March 8, 2024 | finance.yahoo.com

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

March 8, 2024 | globenewswire.com

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

February 23, 2024 | finanznachrichten.de

Athira Pharma, Inc.: Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

February 22, 2024 | globenewswire.com

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

February 8, 2024 | finance.yahoo.com

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

February 6, 2024 | uk.investing.com

Athira Pharma Inc (ATHA)

January 22, 2024 | finance.yahoo.com

With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors

January 11, 2024 | markets.businessinsider.com

Athira Pharma: A Buy Rating Backed by Promising Alzheimer’s Drug Prospects and Strong Cash Position

January 10, 2024 | bizjournals.com

Athira Pharma's chief medical officer retires

January 8, 2024 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)

January 8, 2024 | finance.yahoo.com

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

January 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Athira Pharma as LIFT-AD Trial Progresses with Promising Prospects and Solid Financial Standing

January 3, 2024 | finanznachrichten.de

Athira Pharma, Inc.: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

January 2, 2024 | msn.com

Athira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 shares

December 25, 2023 | benzinga.com

Athira Pharma Stock (NASDAQ:ATHA) Dividends: History, Yield and Dates

December 15, 2023 | markets.businessinsider.com

Optimistic Outlook for Athira Pharma Despite Setback: Buy Rating Affirmed

See More Headlines

Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ATHA
CUSIP: N/A
CIK: 1620463
Web: athira.com
Phone: 425-620-8501
Fax: N/A
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $19.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +485.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-117,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -69.11%
Return on Assets: -59.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.37
Quick Ratio: 5.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.42 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 38,330,000
Free Float: 32,616,000
Market Cap: $78.58 million
Optionable: Optionable
Beta: 2.77

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Mark J. Litton M.B.A. (Age 56)
Ph.D., President, CEO & Director
Comp: $882.7k
Dr. Kevin Church Ph.D. (Age 39)
Chief Scientific Officer
Comp: $123.67k
Ms. Julie Rathbun
Head of Investor Relations
Mr. Mark F. Worthington J.D. (Age 58)
General Counsel & Corporate Secretary
Comp: $503.83k
Ms. Samantha Willing
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings or view top-rated stocks.
What is Athira Pharma's stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price objectives for Athira Pharma's stock. Their ATHA share price targets range from $5.00 to $19.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 482.5% from the stock's current price.
View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts.
How have ATHA shares performed in 2024?: Athira Pharma's stock was trading at $2.43 on January 1st, 2024. Since then, ATHA shares have decreased by 15.2% and is now trading at $2.06.
View the best growth stocks for 2024 here.
When is Athira Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATHA earnings forecast.
How were Athira Pharma's earnings last quarter?: Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, February, 22nd. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.25.
What ETF holds Athira Pharma's stock?: Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 3.87% of its portfolio.

What other stocks do shareholders of Athira Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).
When did Athira Pharma IPO?: Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.
Who are Athira Pharma's major shareholders?: Athira Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirador Capital Partners LP (0.05%). Insiders that own company stock include Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington.
View institutional ownership trends.
How do I buy shares of Athira Pharma?: Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Athira Pharma (ATHA) Stock Price, News & Analysis

Athira Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Athira Pharma Stock (NASDAQ:ATHA)

ATHA Stock Price History

ATHA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ATHA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™